Background/Aims: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), also known as CD66a, is a member of the immunoglobulin (Ig) superfamily that belongs to the carcinoembryonic antigen (CEA) family which plays a dual role in cancer. Previous studies showed high expression of CEACAM1 in multiple myeloma (MM). The aim of this study was to investigate the biological consequences of CEACAM1 overexpression in MM. Methods: pEGFP-N1-CEACAM1 and pcDNA3.1-CEACAM1 expression plasmids were transfected into U-266 and RPMI8266 cell lines . Effect of CEACAM1 overexpression on the proliferation of two cell lines were tested by the CCK8 assay. Cell cycle and Apoptotic changes after CEACAM1 transfection were examined with AnnexinV-FITC/PI by flow cytometry. Hochest staining assay was used to confirm the apoptotic changes. Caspase-3 activity was examined by Western blotting. The cell invasion and migration activity change after CEACAM1 transfection were performed by well chamber assays and a wound healing, respectively. MMP-2 and MMP-9 proteins expression were detected by Western blotting. Flow cytometry immunophenotyping was be evaluated on myeloma cells from bone marrow taken from 50 patients with symptomatic MM newly diagnosed. The correlations between CEACAM1 expression levels and the clinical features across all groups were investigated. Results: CEACAM1 overexpression significantly suppressed MM cell proliferation, induced cell apoptosis, and inhibited cell invasion and migration possibly through activation of caspase-3 and downregulation of MMP-2 and MMP-9. CEACAM1 expression in patients with DS stage I was more frequent (61.5%) than those with DS stage II (21.1%) or III (22.2%). Furthermore, patients with β2-microglobulin levels equal to or less than 3.5 mg / L had higher CEACAM1 expression than those with β2-microglobulin levels greater than 3.5 mg / L. Conclusion: Our findings suggest that CEACAM1 may act as a tumor suppressor in MM.
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma

Introduction
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a member of the immunoglobulin (Ig) superfamily that belongs to the carcinoembryonic antigen (CEA) family. It is also known as CD66a and was previously characterized as an adhesion and signaling molecule in epithelial, endothelial, hematopoietic, and tumor cells [1] . CEACAM1 has been implicated in various types of intercellular adhesion and intracellular signaling events important in cell survival, differentiation and growth in both normal and cancer cells [2, 3] . An interesting feature of CEACAM1 is that it plays a dual role in different cancers. Studies have shown that CEACAM1 expression in colon, hepatoma and prostate cancers can inhibit tumor growth. Loss of gene expression or downregulation has been frequently observed, indicating that it may act as a tumor suppressor [4] [5] [6] [7] [8] . CEACAM1 overexpression in thyroid and non-small cell cancer and melanomas are often associated with poor clinical outcome and poor survival [8] [9] [10] [11] .
In hematologic malignancies, CEACAM1 expression has been reported in childhood acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and in acute myeloid leukemia (AML) [12] . Ratei et al. reported that CEACAM1 was frequently co-expressed with CD65, CD15, and CD64 in AML [13] . It is also co-expressed, although less frequently, with CD13, CD33, and the two progenitor markers CD34 and CD117. Several studies have shown that CEACAM1 is abnormally expressed on the cell membrane in B-lymphocytes in acute B-lymphoblastic leukemia (B-ALL) [12] [13] [14] . Zhao et al. reported that inhibition of CEACAM1 in B-ALL cell lines resulted in reduced cell proliferation and increased percent apoptosis [15] . CEACAM1 expression in multiple myeloma (MM) was first reported by Satoh et al. in 2002 [16] . Lee et al. reported that CEACAM1 expression rate ranged from 69% to 100% in plasma cells from five MM patients [17] . However, little is known about the biological consequences of CEACAM1 overexpression in MM.
The objective of the present study was to investigate proliferation, cell cycle progression, apoptosis, migration, and invasion in MM cell lines overexpressing CEACAM1. In addition, CEACAM1 expression was evaluated by flow cytometry analysis on myeloma cells from bone marrow from 50 patients with MM. Possible relationships between CEACAM1 expression and patient characteristics were investigated.
Materials and Methods
Cell lines and culture
Two human myeloma cell lines (U-266 and RPMI8266) were obtained from Jiangsu Institute of Hematology (Jiangsu, China). The cells were cultured in RPMI 1640 (Hyclone, USA) with 10% fetal bovine serum (Gibco, USA) and maintained at 37°C with 5% CO 2 .
Plasmid construction and transfection
Full-length CEACAM1 cDNA was amplified by PCR, and was subcloned into pEGFP-N1 or pcDNA3.1 vectors. The primers used for amplifying full length CEACAM1 ORF were as follows: forward: 5'-GCCAGCAGGAGACACCAT-3'; and reverse: 5'-TCATCTTGTTAGGTGGGTCATTG-3'. An empty expression plasmid of the same type was used as a control. All constructed plasmids were confirmed by DNA sequencing. Lipofectamine 2000 (Invitrogen, USA) was used for plasmid transfection according to the manufacturers' instructions. Cells were selected using selection media G418 (Invitrogen, USA). The transfected cells were maintained in RPMI 1640 medium with 10% fetal bovine serum, penicillin (10 U/ml), and streptomycin (10 mg/ml).
In vitro Cell Viability Assay
The stably transfected cells were seeded into 96-well plates (10, 000 cells / well), and maintained in RPMI 1640 as described above. Ten microliters of CCK-8 solution was added in each well. The plates were incubated for 3 hours and sampled at 0, 24, 48, or 72 hr time points afterwards. The absorbance was measured at 450 nm and normalized to the cell counts. 
RNA extraction and RT-PCR.
Total RNA was extracted using Nucleic acid PrepStation from Tiangen Biotech (Beijing, China) according to the manufacturer's instructions. The concentration, quality, and purity of RNA were measured by a UV spectrophotometer at 260 / 280 nm. cDNA synthesis was performed using High Capacity cDNA Reverse Transcription Kit (Life Technologies, USA）following manufacturer's instructions. The mixture was then incubated at 42 °C for 1 h. The enzyme was inactivated by heating at 95°C for 5 min. The primer sequences used for PCR amplification were as follows: 5'-CTCTCCTGCTATGCAGCCTC-3' (reverse primer) and 5'-ACTGAGTTATTGGCGTGGCA-3' (forward primer) for CEACAM1; 5'-CTGTCACCTTCACCGTTCCAGTTT -3' (reverse primer) and 5'-CTTAGTTGCGTTACACCCTTTCTTG -3' (forward primer) for ß-actin. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed in a total volume of 20 μL, containing 50 ng cDNA, 1μM of each primer, 1 μM SYBR Green, and 10 μL 2×Taq PCR Master-mix. Amplification was performed in an Exicycler TM 96 qPCR system. The amplification conditions included a denaturation step at 95°C for 5 minutes followed by 40 cycles of 15 seconds at 95°C, 45 seconds at 58°C to 60°C, and 45 seconds at 72°C. A melting curve cycle was carried out as the last step. The data was analyzed using ExicyclerTM 96 software. Samples were tested in triplicates and the mean cycle numbers were included in the analysis. The relative fold change was normalized against β-actin. The CEACAM1 mRNA expression relative to β-actin was calculated using the 2 -DDCT method.
Assay for CEACAM1-induced apoptosis
Apoptotic cell death was evaluated using a FITC-annexin V/propidium iodide (PI) double-staining kit (KeyGEN Biotech, Nanjing, China) following manufacturer's instructions. Briefly, the cells were washed with PBS and resuspended in 500 μL binding buffer with 5 μL annexin V and 10 μL propidium iodide. The apoptosis assay was performed 48 hr after transfection. Stained cells were analyzed by flow cytometry. Hoechst Staining Kit (Beyotime, Shanghai, China) was also used to confirm apoptotic changes in the cell lines after transfection. The fluorescence microscopy showed the presence of typical apoptotic bodies as dense particles emitting bright blue fluorescence signals indicative of pyknosis in both cell lines. Experiments were repeated independently at least three times using both methods and similar results were obtained.
Cell cycle analysis by flow cytometry
After a 48 hr transfection period, cells were washed with PBS and fixed in 75% ethanol at 4°C overnight. After a 24 hr fixation period, the cells were washed with PBS and treated with propidium iodide (PI) stain (KeyGEN Biotech, Nanjing, China) for 30 min. Then stained cells were analyzed by flow cytometry.
Cell migration and invasion assays
To measure the cell invasion activity, trans-well chamber assays were performed using a BD BioCoat Matrigel Invasion Chamber (BectonDickinson, MA). Cells were resuspended in serum-free RPMI-1640 and then added to the upper chamber at a density of 5×10 4 cells/insert. RPMI-1640 containing 10% FBS was added to the lower chamber. After incubation at 37˚C for 24 hr, the cells that invaded into the lower chamber were counted. To measure the cell migration activity, trans-well chamber assays were performed using BD BioCoat Cell Culture Inserts (Becton-Dickinson) following a protocol similar to that described above for the cell invasion assay. A wound healing assay was also performed to determine the migration activity. The monolayer was scratched with a pipette tip. The cultures were then incubated for 24 hr and the number of cells migrating over the exposed dish surface were recorded.
Western blotting analysis
Whole cell extracts were prepared using the M-PER reagent (Life Technologies, Rockford, USA). Proteins were separated by SDS-PAGE (Bio-Rad Laboratories), transferred to polyvinylidene fluoride membranes (Millipore, USA), blocked for 1 hour in buffer containing 5% nonfat dry milk (Lab Scientific), and incubated with the primary antibody overnight at 1/100 dilution. Rabbit anti Caspase-3 polyclonal antibody (Catalog number: AC033), rabbit anti MMP-2 polyclonal antibody (Catalog number: AF0234), and rabbit anti Cyclin D1 polyclonal antibody (Catalog number: AF0126) were purchased from Beyotime (Shanghai, China). Anti-CEACAM1 rabbit polyclonal antibody (Catalog number: D120408) was purchased from Sangon biotech (Shanghai, China). Rabbit anti MMP-9 polyclonal antibody (Catalog number: 3582) was purchased from Cell Signaling Technology (Boston, MA, USA). Mouse anti β-actin (Catalog number: AF0003) was purchased from Beyotime (Shanghai, China), and used at a 1/1, 000 dilution. Secondary antibodies (IRDye 800CW and IRDye 680LT) purchased from LI-COR(Lincoln,USA ) were used at 1/5, 000 dilution. Secondary an- 
CEACAM1 expression by flow cytometry analysis
Flow cytometry immunophenotyping was performed on myeloma cell populations using a Navios flow cytometer (Beckman Coulter, Inc, USA). All cases were tested using a panel of antibodies raised against leukocyte and plasmacyte-associated markers including surface fluorochrome-conjugated antibodies against CEACAM1, CD45, CD19, CD38, CD56, CD138, CD7, CD34, CD10, CD20, CD13, CD14, CD33, CD15, CD117 and HLA-DR (Beckman Coulter, Inc, Indianapolis, USA). Surface antigen expression was considered positive when over 20% of the plasmacytes were positive for the signal. Statistical Analysis SPSS software version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for all analyses. The correlations between CEACAM1 expression levels and the clinical features across all groups were investigated using Fisher's exact test for categorical data and the nonparametric Mann-Whitney U test for continuous variables. For the quantitative data javascript:void(0);comparisons between treated and control groups, a paired t-test or two-way ANOVA analysis was performed. A P value less than 0.05 was considered statistically significant.
Results
Effect of CEACAM1 overexpression on the proliferation of U266 and RPMI 8266 cell lines
peGFP-N1-CEACAM1 and pcDNA3.1-CEACAM1 expression plasmids were constructed and successfully transfected into the U266 and RPMI8266 cell lines, respectively (Fig. 1a (Fig. 1d) .
CEACAM1 overexpression in MM cells induced apoptosis possibly via increasing caspase-3 activity and affecting cell cycle progression by down-regulating cyclinD1
Both pcDNA3.1-CEACAM1 stably transfected and non-transfected U-266 and RPMI8266 cell lines were incubated for 48 hr and then examined for the cells positive for AnnexinV-FITC/PI to determine apoptosis by flow cytometry. Apoptosis rates after CEACAM1 transfection were increased in both U-266 and RPMI8266 compared to the non-transfected cells (Fig.  2a) . We also used Hochest staining assay to confirm the apoptotic changes in the two cell lines after transfection. The fluorescence microscopy showed the presence of typical apoptotic bodies as dense particles emitting bright blue fluorescence due to pyknosis in both U-266 and RPMI8266 cells (Fig. 2b) . Western blotting analysis showed that caspase-3, the main terminal enzyme in the apoptotic process, was activated after CEACAM1 transfection in both U-266 and RPMI8266 cell lines (Fig. 2d) .
Cell cycle analysis after transfection showed a marked growth arrest in the G1 phase in both cell lines. Compared to the control group, CEACAM1 transfection significantly reduced the number of cells in the S phase, with no significant impact on the number of cells in the G2 cycle (Fig. 2c) . Western blotting analysis showed that cyclinD1 was inhibited after CEACAM1 transfection in both cell lines (Fig. 2d) .
CEACAM1 expression inhibits cell invasion and migration
In the wound healing assay, the wounded area in the U-266 and RPMI8266 cell lines began to close at 12 hr and was covered with migrating cells within 24 hr, whereas the cells transfected with pcDNA3.1-CEACAM1/U266 and pcDNA3.1-CEACAM1/RPMI8266 had more uncovered areas at 24 hr (Fig. 3a) . The number of invading cells in cells transfected with pcDNA3.1-CEACAM1/U266 and pcDNA3, 1-CEACAM1/RPMI8266 were lower than those in the control cell lines (Fig. 3b) . Transfection decreased the expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) proteins, the two very important mediators of tumor migration ( Fig.  3c and 3d) .
CEACAM1 expression in MM patients is associated with disease stage (DS) and β2-microglobulin expression
We also compared CEACAM1 expression in the healthy subjects and MM patients with different β2-microglobulin levels. CEACAM1 expression was 3% in the healthy subjects, 31.45% in the patients with β2-microglobulin greater than 3.5 mg/L and 96.89% in the patients with β2-microglobulin levels less or equal to 3.5 mg/L (Fig. 4) .
Positive CEACAM1 expression was more frequent in DS stage I than the DS stage II or III groups of patients (P < 0.05). However, there were no significant correlations between CEACAM1 expression levels and the age, gender, percentage of bone marrow myeloma cells, chromosome karyotype, type of light chain, M-protein, IgH rearrangement, or renal function (Table 1) .
Discussion
CEACAM1 was originally discovered in the bile, but a subsequent immunohistochemical study disclosed a wide tissue distribution [11] . With regard to hematopoietic tissues, its expression has been reported in granulocytes, lymphocytic tumor cells, activated T lymphocytes, natural killer (NK) cells, and intestinal intraepithelial lymphocytes, suggesting that Fig. 2 . Effect of CEACAM1 overexpression on the apoptosis and cell cycle in U-266 and RPMI8266 cell lines. a, Cells were incubated for 48 hr, then examined by flow cytometry for apoptosis by determining the number of cells positive for AnnexinV-FITC/PI. The apoptosis rate in the U-266 and RPMI8266 after CEACAM1 transfection were both increased compared to the control. b, Hochest staining assay was used to confirm the apoptotic changes in the U-266 and RPMI8266 cell lines after transfection with CEACAM1 pcDNA3.1 vectors. Compared to the parental cells, the apoptosis ratio were elevated in both cell lines after transfection. The (**) denotes P<0.01 c, Cell cycle analysis after CEACAM1 transfection showed a marked growth arrest in the G1 phase in both cell lines. Compared to the control group, CEACAM1 transfection significantly reduced the cell number in S phase, with no significant impact on the number of cells in the G2 cycle. d, western blotting analysis showed that caspase-3 was activated but cyclinD1 was inhibited after CEACAM1 transfection in both U-266 and RPMI8266 cell lines. CEACAM1 may play an important role in normal and transformed lymphocyte functions [3] . Expression of CEACAM1 in multiple myeloma was first discovered by Satoh et al. in 2002 [16] . Previously, others showed that CEACAM1 is down-regulated or dysregulated in carcinomas [18] . For example, in prostate cancer, CEACAM1 is lost during the progression from Gleason stage 3 to 4 [19, 20] . It is also down-regulated in colon carcinomas, hepatocellular carcinomas [21] , and in a proportion of breast cancers. However, it is known for some time that the down-regulation of CEACAM1 is not a general phenomenon in epithelial malignancies [19] . For example, it is up-regulated in gastric and thyroid cancers and metastasing malignant melanomas [22] . Similarly, in non-small cell lung cancer, CEACAM1 is up-regulated and it is an indicator of a poor prognosis [23, 24] . Therefore, CEACAM1 may have different roles in different types of cancers [6] . The role of CEACAM1 in MM has not been well investigated in the literature. Our investigation found that CEACAM1 expression was more frequent in DS stage I than DS stage II or III groups of patients. In addition, CEACAM1 expression was more frequent in patients with β2-microglobulin levels less than or equal to 3.5 mg/L than those with levels greater than 3.5 mg/L. In 2002, Satoh et al., reported that 18 of 21 MM cases (86%) were CEACAM1 positive whereas our results show that only 16 of 50 MM cases (32%) were positive. The most likely reason for this discrepancy could be that the patients analyzed by Satoh et al.and in our study were in different disease stages.
Our observation that the patients with DS I had more frequent CEACAM1 expression than those in DS II or III suggest that CEACAM1 is probably a marker for better prognosis in MM. To further investigate this phenomenon, we transfected full-length CEACAM1 expression plasmids into the U-266 and RPMI8266 cell lines and investigated the effects of CEACAM1 overexpression on cell proliferation, cell cycle, apoptosis, and cell migration and invasion in vitro.
After transfection, the cell count decreased and apoptosis increased in both cell lines compared to the non-transfected controls. These findings suggest that CEACAM1 overexpression could suppress MM cell proliferation and induce apoptosis. Cell cycle analysis after transfection showed a marked growth arrest in the G1 phase in both cell lines. Compared to the control group, CEACAM1 transfection significantly reduced the cell number in S phase, with no significant impact on the number of cells in G2 phase. The fluorescence microscopy showed that the typical apoptotic bodies were more obvious in the U-266 and RPMI8266 cell lines after CEACAM1 transfection, and the western blotting analysis showed that caspase-3 expression increased after the transfection in both cell lines. Therefore, the decrease in cell proliferation and increase in apoptosis seen in MM cells overexpressing CEACAM1 in our study maybe due to the caspase-3 overexpression.
In our study, CEACAM1 overexpression resulted in less MMP-2 and MMP-9 protein expression and lower invasion and migration compared to the control cell lines. These results suggest that decreased invasion and migration in MM cells could be due to downregulation of MP-2 and MP-9 protein expression. Ebrahimnejad et al., on the other hand, reported that CEACAM1 enhanced invasion and migration in melanocytic and melanoma cells. The authors concluded that CEACAM1 actively contributed to tumor progression [25] . The reason for this discrepancy warrants further investigation but could be that CEACAM1 may have different roles in different cancers as discussed above [26, 27] .
Conclusion
Our data show that CEACAM1 overexpression in MM cell lines exerts an anti-tumor effect, suggesting that CEACAM1 may be acting as a tumor-suppressor in MM. To our knowledge, this is the first study clarifying the functional role of CEACAM1 in MM in vitro.
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